The Design of New Adjuvants for Mucosal Immunity to Neisseria meningitidis B in Nasally Primed Neonatal Mice for Adult Immune Response by Ferreira, Tatiane & De Gaspari, Elizabeth
The Scientiﬁc World Journal
Volume 2012, Article ID 292073, 14 pages
doi:10.1100/2012/292073 The  cientiﬁcWorldJOURNAL
Research Article
The Design of New Adjuvants for Mucosal Immunityto
Neisseriameningitidis B in Nasally Primed Neonatal Mice for
AdultImmune Response
TatianeFerreiraandElizabethDe Gaspari
Immunology Department, Adolfo Lutz Institute, Avenue Dr. Arnaldo 355, 11 andar, 01246-902 S˜ ao Paulo, SP, Brazil
Correspondence should be addressed to Elizabeth De Gaspari, egaspari@ial.sp.gov.br
Received 31 October 2011; Accepted 30 November 2011
Academic Editor: Monica Vieira
Copyright © 2012 T. Ferreira and E. De Gaspari. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
The aim of this study was to determine the value of detoxiﬁed Shiga toxins Stx1 and Stx2 (toxoids of Escherichia coli)a sm u c o s a l
adjuvants in neonatal mice for immunogenicity against the outer membrane proteins (OMPs) of Neisseria meningitidis B. Mucosal
immunization has been shown to be eﬀective for the induction of antigen-speciﬁc immune responses in both the systemic and
mucosal compartments. Systemic antibody levels (IgG, IgG1, IgG2a, IgG2b, IgM, and IgA) and mucosal IgM and IgA were
measuredbyELISAusinganN.meningitidisas anantigen.Inaddition,IFN-γ andIL-6productionweremeasuredafterstimulated
proliferation of immune cells. Intranasal administration elicited a higher anti-OMP IgA response in both saliva and vaginal ﬂuids.
Our results suggest that both Stx1 and Stx2 toxoids are eﬀective mucosal adjuvants for the induction of Ag-speciﬁc IgG, IgM,
and IgA antibodies. The toxoids signiﬁcantly enhanced the IgG and IgM response against OMPs with a potency equivalent to
CT, with the response being characterized by both IgG1 and IgG2a isotypes, and increased IFN-gamma production. Additionally,
bactericidal activity was induced with IgG and IgM antibodies of high avidity. These results support the use of the new toxoids as
potent inducing adjuvants that are particularly suitable for mucosal immunization.
1.Introduction
The development of eﬃcient and safe adjuvants for use in
humanvaccinesremainsbothachallengeandanecessity[1].
As the most widely used adjuvants in humans, aluminum
salts predominantly induce antibody responses; therefore,
discovering new adjuvants is crucial for the development of
vaccines that require a cell-mediated response [2, 3].
Although much of the adjuvant research that was carried
out in the past can be seen as empirical, the research did
sometimes give rise to potent and useful products. Nev-
ertheless, there is a need to develop a new generation of
adjuvants that are rationally designed on the basis of recent
progress that has been made in our understanding of the
immune response, particularly the innate immune response.
Additional adjuvant research into the development of eﬀec-
tive mucosal vaccines is also necessary to compensate for
the often poor immunogenic nature of orally and nasally
administered vaccine antigens by instead inducing vaccine
antigen-speciﬁc humoral and/or cellular immune responses
[4].
We know that eﬀorts to develop new strategies to curb
global infection in the ﬁeld are important and currently the
development of novel adjuvants that can be nasally or orally
administered vaccine antigens to maximize the induction
protective antibodies is under investigation in several lab-
oratories. Thus far, several bacterial enterotoxins, including
cholera toxin (CT) of Vibrio cholerae and heat-labile entero-
toxin (LT) of enterotoxigenic Escherichia coli,h a v eb e e n
identiﬁed as possessing strong immunoenhancing activity
against coadministered protein antigens when administered
by oral or nasal routes [5, 6].
Neisseriameningitidisisamajorcauseofbacterialmenin-
gitis in the human population, especially among young
children. There is a need to develop a noncapsular vaccine
to prevent meningococcal B infections due to the inadequate
immune response elicited against the capsular polysaccha-
ride of these strains. A vaccine inducing protection against2 The Scientiﬁc World Journal
most of the circulating variants of serogroup B meningo-
coccal strains is not yet available. Several outer membrane
protein- (OMP-) based vaccines for group B meningococcal
disease have shown 50 to 80% eﬃcacy in older children
[7]. However, eﬃcacy in young children receiving the same
vaccines was much lower, despite the induction of high levels
of antibody [8].
Colonization of the human nasopharyngeal region by
N. meningitidis is believed to lead to natural immunity. In
some cases, this colonization also initiates the pathogenic
process that leads to invasive meningococcal disease. Serum
bactericidal antibody, which develops after exposure to
meningococcal antigens [9, 10], has been correlated with
immunity to meningococcal disease, but mucosal immunity
at the portal of entry may also play an important role. A
number of plausible options are currently under investiga-
tion as a mucosal vaccine to this pathogen [11].
Shiga toxin (Stx) was found to possess immunogenicity
but not adjuvant activity when given via the oral route
[12]. Stx, which is generated by Stx-producing E. coli
(STEC), is one of the major virulence factors for STEC
infectious diseases. Stx is a holotoxin composed of an A
subunit measuring approximately 32kDa in a noncovalent
association with a pentameric ring of identical B subunits,
each with a molecular mass of 7.7kDa [13]. Stxs, which are
also known as Shiga-like toxins or Vero toxins, are produced
by the enteric pathogens Shigella dysenteriae and enterohem-
orrhagic E. coli (EHEC).
Stx is classiﬁed into two groups: Stx1, the amino acid
sequence which is identical to that of Shiga toxin, and Stx2,
which is immunologically distinct from Stx1 [14].
In an eﬀort to develop a candidate adjuvant for a
vaccine against infectious diseases caused by N. meningitidis
B, we have assessed the capability of nasally administered
detoxiﬁed Stx1 or Stx2 toxins (toxoids) with the OMP of
N. meningitidis. In this study, we used newborn mice (1-2
weeks of age), which reﬂect the ﬁrst year of a human infant’s
immune maturation in many aspects, as a model [15].
This study is preceded by another published work by
Ohmura-Hoshino et al. [16] that described the nontoxic
Stx derivatives from E. coli possessing adjuvant activity for
mucosal immunity. Ohmura et al. used ovalbumin as an
antigen and Stx1 as an adjuvant for nasal immunization of
adult mice.
2.MaterialsandMethods
2.1. Bacterial Strains and Antigen Preparation. The Brazilian
epidemic group B meningococcal strain (B:4:P1.15,19,5.5,
L3,7,9,1,8) was selected for use in this study. The bac-
teria were grown overnight in a candle jar on Tryptic
Soy Broth (TSB; Difco BRL products, Gaithersburg, MD)
supplemented with 1% horse serum (Sigma, St. Louis,
MO) in plates in a 5% CO2 atmosphere at 37◦C. The
OMP were prepared by extraction of bacteria with 0.5%
deoxycholate in 0.1M Tris-HCl buﬀer (pH 8.6) containing
10mM EDTA and puriﬁed by diﬀerential centrifugation
[17]. E. coli used in these experiments was obtained from
clinical samples from the state of Bahia, Brazil, and was
designatedas(C7-88)O157:H7(Stx1)and(1189)ONT:H49
stx2+stx2vb−hb (Stx2) [18]. They were kindly provided
by Dr. Roxane Piazza (Bacteriology Laboratory—Butantan
Institute, S˜ ao Paulo, Brazil). E. coli bacterial strains were
grown in Luria-Bertani (LB) medium supplemented with
appropriate antibiotics at 37◦C for 18h under constant
shaking (200rpm). The toxins were detoxiﬁed as previously
described [19]. Bacteria were centrifuged at 5000xg, and
the supernatant was ﬁltered through a 0.45μmm e m b r a n e .
These conditions were employed in all experiments. The
total protein concentration was determined by the Bradford
method using reagents from BioRad (Hercules, CA, USA)
and serum albumin as the standard [20].
2.2. Animal Experiments. For the generation of newborn
mice, pregnant females were separated and caged individ-
ually, and newborns were maintained with their mothers
during the experiments. Groups of BALB/c H-2d haplotype
neonatal mice were immunized 4 times during 12 days (days
3, 7, 9, and 12) by intranasal (i.n.) immunization with 20μg
of N. meningitidis OMP and 2μg of Stx1 or Stx2 toxoids,
an e wm u c o s a la d j u v a n t[ 17], or CT, applying 2.5μLp e r
nostril. In another set of experiments, the immunization
was performed with the same amount of saline plus adju-
vants Stx1, Stx2, or CT, or OMP as experimental controls
for immunization. The immunogenicity of the diﬀerent
formulations containing OMP and Stx1, Stx2, or CT was
assessed using female BALB/c mice. Mice were distributed
into four groups. Serum samples were taken at 28 days after
i.n. immunization and 42 days after i.m. immunization. On
day 42, mice were sacriﬁced and spleen cells were obtained
for cytokine determinations. Serum was obtained from the
mice 28 days after i.n. immunization or at 42 days i.m by
retro-orbital puncture after i.m. immunization on the 35th
day with OMP (20μg) and 2μg of Stx1 or Stx2 as adjuvants.
Additionally, New Zealand white rabbits (CRIEX Laborato-
ries, S˜ ao Paulo, SP, Brazil) weighing 2.25 to 3.5kg were used
in all experiments. We used three rabbits for each experi-
mental group. Prime boosters were administered with i.n.
and i.m. immunizations in unanesthetized rabbits. Rabbits
were held in a supine position and a ﬂexible micropipettor
was used to drip 500μL( 5 0μg of stx1 or stx2) of toxoid into
the naris, with about half the volume in each nari as
described previously [21]. All procedures with the animals
were in accordance with the guidelines of the Brazilian Code
for the Use of Laboratory Animals.
2.3. Monoclonal Antibodies. Murine anti-Stx1 and anti-Stx2
mAbs were secreted from hybridomas generated by a fusion
between the lymph node cells of BALB/c mice immunized
with Stx1 or Stx2 toxoids and P3.653 Ag 8 myeloma cells, as
described previously [22–25]. To test the action and speci-
ﬁcity of these mAbs, the culture supernatant was assayed for
the presence of secreted antibodies by capture ELISA using
biotinylated isotypes mouse antibodies (Kirkegaard and
Perry, Gaithersburg, MD).
2.4. Puriﬁcation of Stx1 and Stx2 Toxoids. The toxoids
were puriﬁed by aﬃnity chromatography through SepharoseThe Scientiﬁc World Journal 3
4B-mAbs for Stx1 or Stx2 produced in our laboratory, as
described by the manufacturer. The antigen was eluted with
0.1M glycine (pH 3.0) and dialyzed in 0.02M PBS (pH
7.2). The antigen was concentrated by ultra-ﬁltration with
a diaﬂomembrane of PM 10 (MW, cut-oﬀ 10,000; Millipore
Corp., MA, USA), and puriﬁcation was veriﬁed by SDS-
PAGE analysis. These two toxins were made nontoxic by
dialyzing them for 7 days at 37◦C in a 100mM sodium phos-
phate buﬀer (pH 8.0) containing 0.6% formaldehyde [26].
Detoxiﬁcation proceeded at 30◦C. The formalized toxin was
sampled at intervals by mouse inoculation until it became
completely nontoxic. At each interval, 2 mice were i.p.
administered with 0.5mL of the sample and then observed
for 4 days. The toxoids were shown to be nontoxic when
mice neither died with the toxicity nor showed any speciﬁc
symptoms of toxicity, such as muscle spasms, stiﬀening, or
any other abnormal signs during the observation period.
The toxoids were kept at −20◦C until use. After puriﬁcation,
endotoxin concentrations in Stx1 and Stx2 toxoids were
determined by the Limulus assay (BioWhittaker). CT was
obtained from Sigma Chemical Co., St. Louis, MO, USA.
2.5. SDS-PAGE. It was performed using a 13% gel. [27].
Brieﬂy, 10μgo fO M Po r3 0μg of the toxoids Stx1 or Stx2
and CT were applied to a 13% SDS-polyacrylamide gel.
After electrophoresis, the separated proteins were transferred
to a nitrocellulose membrane (Hybond C-Extra, Amersham
Biosciences, Little Chalfont, UK) at 100V for 18h at 4◦C.
The membrane was blocked with 5% skim milk for 2h
and reacted with a 1:50 dilution of Stx1 or Stx2 mono-
clonal or polyclonal antibodies. The membrane was then
washed and incubated for 2h with peroxidase-conjugated
goat anti-mouse IgG or IgM (1:2000), or goat anti-rabbit
IgG(1:5000). After washing, the strips were washed, and the
reaction was developed with AEC (Pierce Inc, IL, USA) and
stopped by adding distilled water.
2.6.AntigenSpeciﬁcityoftheAntibodyResponses:Immunoblot.
The samples were analyzed by immunoblotting. Brieﬂy,
10μgo fO M Po r2 0 μg of Stx1 or Stx2 preparation was
analyzed by 13% SDS-PAGE and transferred onto 10mm
PVDF strips (Pierce Inc, Illinois, USA). These strips were
cut and blocked with 5% skim milk in solution for 2h at
room temperature. Samples were diluted 1:50 in blocking
solution and incubated for 18h at 4◦C. The strips were
washed three times in PBS, and peroxidase-conjugated anti-
y, -μ,o r- λ chains, which had been diluted in PBS plus 2.5%
skim milk, were added for 2h. The strips were washed and
the reaction was developed with AEC (Pierce Inc, IL, USA).
Samples were analyzed by ELISA and immunoblotting with
polyclonal antisera. After washing, the plates were incubated
with a 1:2,000 dilution of streptavidin (Sigma Chemical
Co., St. Louis, MO, USA) at 100μL/well for 30min at room
temperatureandwashed6times.TMB(SigmaChemicalCo.,
St. Louis, MO, USA) in 30% H2O2 substrate was added and
the color change reaction was stopped by the addition of 4N
H2SO4. Readings were taken at 450nm using a microplate
spectrophotometer (Multiskan MCC, Lab Systems and Flow
Lab, Finland).
2.7. Cytotoxicity Assay. HeLa (CCL-2) and Vero (CCL-81)
cells were used. The culture protocol recommended by the
American Type Culture Collection (ATCC) was reproduced
bytheAdolfoLutzInstitute(cellculturecollection),andcells
were grown in Minimum Essential Medium Eagle (MEM).
HeLa and Vero cells were plated at approximately 1.4 ×
104 cells/well on 96-well plates in MEM. Cytotoxic eﬀects
of the toxoids were visualized by neutral red (NR) vital
staining containing antibiotics that were prepared one day
before the assay and incubated overnight at 37◦C. The
medium containing the test compound was removed and
replaced with 200μLo f2 5 μg/mL neutral red diluted in
MEM (NR medium without FBS) 3h before termination of
the experiment. After 3 hours, the lysosomes had taken up
suﬃcient NR stain. The NR medium was then removed, the
cells were rinsed twice with preheated PBS to remove excess
unincorporated stain, and, after quickly rinsing in 100μLo f
ﬁxative (0.5% formalin/PBS), 100μL of destain solution (1%
glacial acetic acid, 49% PBS, and 50% ethanol) was added to
each well to ﬁx the cells and remove the NR in the solution.
The plates were gently shaken for 10min on an orbital
shaker and the absorbance of the solution was read at
550nm. For the evaluation of cytotoxicity, the average
absorbance of the media control well, which contained no
chemical, was regarded as 100%, and the percentage of
viable cells in each well was calculated according to (O.D. ×
100)/control media, which is equivalent to the percentage of
viable cells per well [28, 29]. The concentrations of cytokines
were determined with reference to a standard curve for serial
twofold dilutions of murine recombinant cytokines.
2.8. Speciﬁc Antibody Levels. Speciﬁc antibody levels (IgG,
IgG1, IgG2a, IgG2b, IgM, and IgA) were measured by
ELISA. Polystyrene plates (Maxi Sorp, NUNC, Denmark)
were coated overnight at 37◦Cw i t h2μg/well OMP antigen
in 0.5M carbonate/bicarbonate buﬀer, pH 9.6, and washed
with PBS-0.05% Tween, pH 7.4. After blocking for 1h at
37◦C in 5% skim milk (Molico, Nestl´ e) in PBS-0.05% Tween,
pH 7.4, and after ﬁve washes, the samples were diluted in
PBS-0.05% Tween plus 1% skim milk. Anti-IgG, -IgM, -
IgA, -IgG1, -IgG2a, and -IgG2b conjugates (Kirkegaard and
Perry, Gaithersburg, MD) were used as described previously
and the reaction was developed for 20min with a substrate
consistingofTMBand150μLand30%hydrogenperoxidein
30mLPBS,pH7.4.Thereactionwasstoppedbytheaddition
of 4N H2SO4. Readings were taken at 450nm using a
microplatespectrophotometer(MultiskanMCC,Labsystems
and Flow Lab, Filand, USA).
2.9. Collection of Secretion and Serum. Serum samples were
collected28daysafteri.n.immunizationand7daysafteri.m.
immunization. At 7 days after the last i.m. immunization,
100μL of saliva was collected from female mice injected i.p.
with a single injection of 0.1mg Pilocarpine HCL (Sigma
Chemical Co., St Louis, Mo) in 100μL of PBS to stimulate
salivation. Vaginal washes were taken from female mice by
washing 3 times with 100μL of Dulbecco’s medium using
a pipettor ﬁtted with a plastic tip [30]. Saliva was collected
of the mice immediately after salivation that had been4 The Scientiﬁc World Journal
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Figure 1: (a)(1) SDS-PAGE (13% gel) analysis of native OMPs of N. meningitidis; (a)(2) LPS characterization and (a)(3) LPS
immunoreactivity with monoclonal antibodies of N. meningitidis;( b )E. coli stx1 (1) or stx2 (2) toxoid after silver stain. Standard markers
are shown on the left of (a); (c) immunoblot of 13% SDS/PAGE and transfer to nitrocellulose membranes. Nitrocellulose membranes
containing OMPs of N. meningitidis (lanes (c)(1) and (c)(2)) were incubated with 1:500 dilution of rabbit antiserum anti-OMPs-Stx1
or anti-OMPs-Stx2, respectively. Immunoblot with 100μg of toxoid Stx1 or Stx2; Lanes (d)(1) and (d)(2): IgG immunoreactivity of the
monoclonal antibody anti-Stx1 or -Stx2, respectively, with the A subunit of the toxoid.
induced by a single intraperitoneal injection of 0.1mg
Pilocarpine HCL in 100μL of PBS. The samples were frozen
at −20◦C in 1.5-mL microcentrifuge tubes (BioRad) and
subsequently extracted with 500μL of PBS containing 5%
skim milk (Molico, Nestle do Brazil) and the protease
inhibitor PMSF (Sigma Chemical Company, St. Louis, MO,
USA). Conjugated goat anti-mouse antibodies (Kirkegaard
and Perry, Gaithersburg, MD) were used as a conjugate.
2.10. SBA. The serum bactericidal activity (SBA) assay was
performed with an agar overlay method in microtiter plates
as described previously [31]. In brief, twofold dilutions of
sera, starting at 1:2, were tested with a meningococcal
inoculum of approximately 80 to 100 CFU per well of the
homologous N. meningitidis strain, ﬁrst grown overnight
on brain heart infusion agar with 1% horse serum, and
then grown for 4h in a 5% CO2 atmosphere at 37◦C
on a new plate. Baby rabbit sera from an individual
without bactericidal antibodies to the strain were used as
a complement source. Agar was added to the plates after a
30-minute incubation of the reaction mixture at 37◦C. The
numbers of CFU were counted after overnight incubation in
5%CO2 at37◦C.Thetitersaregivenasthehighestreciprocal
ﬁnal dilution of serum killing more than 50% of the in-
oculum.
2.11. Spleen Cell Proliferation Assay. Brieﬂy, mice were sacri-
ﬁced by cervical dislocation and the spleens were aseptically
removed. Spleen cells were harvested by ﬂushing the spleen
with PBS. Red blood cells were eliminated by treatment with
a hypertonic solution of NH4Cl for 3min on ice followed by
centrifugation and washing. Cells were stained with Trypan
blue (Sigma) and resuspended at 8 × 106 cells/mL in RPMI-
1640 medium supplemented with L-glutamine, pyruvate,
gentamicin, penicillin, and 10% FCS. Cells were cultured
in 24-well plates (8 × 106 cells/well, 2mL/well). Culture
supernatants were collected for cytokine determination.
2.12. Evaluation of Cytokine Production In Vitro. The cy-
tokines IFN-γ (48, 72h) and IL-6 (20, 48, 72h) were mea-
sured in culture supernatants by capture ELISA using anti-
body pairs purchased from PharMingen (San Diego, CA)
according to the manufacturer’s instructions.
2.13. Statistical Analysis. One-way ANOVA statistical test
was used to assess the signiﬁcance of the diﬀerences between
the various groups. In case of signiﬁcant F-value, multiple
comparison Tukey test was used to compare the means of
diﬀerent treatment groups and P<0.05 was considered to
be statistically signiﬁcant.
3. Results
3.1. Electrophoretic Analysis. Figure 1 analyzed the OMP of
N.meningitidisbySDS-PAGEwithCoomassieblueandsilver
staining or monoclonal antibody reactivity to Stx1 or Stx2
toxins and toxoids of E. coli. SDS-PAGE after Coomassie
staining showed the antigenic characterization of the N.
meningitidis OMP. We observed proteins of 13 to 120kDa,
with major proteins of 46kDa (class 1—PorA) and 38kDa
(class3—PorB)proteinsandamajorproteinof28kDa(class
5). The major OMPs of meningococcus have been classiﬁed
on the basis of molecular weight and behavior on SDS-PAGE
[32]. This antigen preparation was used for immunization
Figure 1(a)1. For a better characterization of N. meningitidis
strain used in this study the Figure 1(a)2 shows the antigenic
characterization of N. meningitidis LPS after silver staining,
and Figure 1(a)3 shows antigens lower than 10kDa. Also
Figure 1(a)3 shows immunoblot reacted with three diﬀerent
monoclonal antibodies. The bands at position 3.1 reacted
with antibody WBE12-C10 L3,7,9, (5.9kDa), 3.2 reacted
with L1 (4.8kDa) 3G3-1-8C, and 3.3 reacted with (3.6KDa)
L8, the 6E7-10 monoclonal antibody. The puriﬁed Stx1
and Stx2 toxoids and the native toxins of E. coli were
also analyzed by SDS-PAGE in Figures 1(b)1 and 1(b)2The Scientiﬁc World Journal 5
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Figure 2: Antigen-speciﬁc IgG, IgM, and IgA antibody responses in mice sera after i.n. immunization with native OMPs of N. meningitidis
determined by ELISA at 28 days with Stx1, Stx2, or CT as adjuvants. Results are shown as mean titers and error bars indicate standard
deviations from the mean. (a) Sera pooled from nine mice immunized with OMPs and stx1; (b) sera pooled from eight mice immunized
with OMPs and stx2; (c) sera pooled from ten mice immunized with OMPs and CT. (1) IgG, IgM, and IGA of normal mice; (2) IgG; (3) IgM;
(4) IgA. Each scale bar represents the mean ± SE of nine to ten mice per group in an experiment representative of two separate experiments.
(a) OMPs and Stx1- IgG, IgM, and IgA containing formulations versus normal sera (P<0.0 5 ) ;( b )O M P sa n dS t x 2I g G ,I g M ,a n dI g A
containing formulations versus normal sera (P<0.001); (c) OMPs and CT IgG, IgM, and IgA containing formulations versus normal sera
(P<0.05).
andinFigures1(c)1and1(c)2,respectively.WithSDS-PAGE,
we can see a pattern of Stx1 and Stx2 toxins in Figures
1(b)1 and 1(b)2 and the concentrated toxoids Stx1 and
Stx2 with peptides in the range of 30 to 100kDa, respec-
tively. The immunoblot (D 1,2) was reacted in sequence with
two diﬀerent monoclonal antibodies against the A subunit of
Stx1 and Stx2, respectively.
3.2. Cytotoxicity. Stx1 and Stx2 toxoids of E.coli strains used
were consequently tested for cytotoxicity using the cultured
supernatants of Vero and HeLa cells. We have used a quan-
titative colorimetric method based on the uptake of NR dye,
which accumulates in the lysosomes of uninjured cells. After
detoxiﬁcation with formaldehyde, neither stx1 nor stx2 was
c y t o t o x i ct oV e r oo rH e L ac e l l s( d a t an o ts h o w n )[ 28, 29].
3.3. Detection of IgG, IgM, and IgA in the Sera from Mice by
ELISA. We evaluated the immunogenicity of the OMP from
N. meningitidis following i.n. delivery with Stx1, Stx2 or
CT as an adjuvant in neonatal mice (Figures 2(a)–2(c))a n d
i.n./i.m. immunization in adult mice that induced high
titers of speciﬁc antibodies. We veriﬁed that the OMPs of
N. meningitidis induced antibody titers in adult BALB/c
mice corresponding to the toxoids used. To better interpret
these results, we used the ratio between the values of the
postimmunization serum samples and the value of the
preimmune sera compared with the normal sera. Increases
in the antibody titers suggested that four doses of OMP in
mice in neonates successfully primed the immune system of
micetogeneratefastIgG,IgM,andIgAantibodyproduction.
We observed a fast production of antibodies 7 days after the
boost.
3.4. The Prime-Boost Immunization Protocol Induces a Th1-
Biased Response. To evaluate the eﬀect of the vaccination6 The Scientiﬁc World Journal
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Figure 3: Antigen-speciﬁc IgG, IgM, and IgA antibody responses in serum stimulated after i.n./i.m. immunization with native OMPs of N.
meningitidis at 42 days, 7 days post the i.m prime-boost, in the presence of stx1, stx2, or CT as adjuvants. (b) Sera pooled from nine mice
immunizedwithOMPsandstx1;(a)serapooledfromeightmiceimmunizedwithOMPsandstx2;(c)serapooledfromtenmiceimmunized
with OMPs and CT. (1) IgG, IgM, and IgA of normal mice; (2) IgG; (3) IgM; (4) IgA. Each scale bar represents the mean ± SE of nine to ten
micepergroupinan experiment representative oftwoseparateexperiments. (a)OMPsand stx1-IgG,IgM,and IgAcontainingformulations
versus normal sera (P<0.001), (b) OMPs and stx2 IgG, IgM, and IgA containing formulations versus normal sera (P<0.001); (c) OMPs
and CT IgG, IgM, and IgA containing formulations versus normal sera (P<0.05).
strategy on the elicited IgG response, we analyzed the
predominance of the IgG1, IgG2a, or IgG2b isotypes,
Figure 5—representative of Th2- and Th1-type immunity,
respectively—within the pool of speciﬁc serum antibodies
using OMP Stx1 or Stx2 toxoids or CT. As previously
reported by our group, when the prime-boost schedule was
used with other antigens, such as NOMV of N. lactamica in
neonatal [27] or adult mice [33] with a puriﬁed protein of
N. meningitidis, an immune response could be induced
quickly.
3.5. Mucosal Immune Response. We analyzed the level of
IgA produced with the new toxoids compared with CT in
nasal and vaginal ﬂuids after immunization Figure 4.T h e
formulations induced a good immune response on the 42th
day after immunization at the mucosal level in the groups
of mice primed during the neonatal period (Figure 3(a)).
In addition, the IgA antibodies could be compared with
t h ev a g i n a ls e c r e t i o n s( Figure 3(b)). Diﬀerences in salivary
IgA anti-OMP responses were observed on the 42th day
after immunization (Figure 3(a)). However, no signiﬁcant
diﬀerences were detected between groups using the new
toxoids compared with the classical mucosal adjuvant CT in
i.n./i.m-immunized groups compared to saliva and intrav-
aginal secretion (Figure 3(c)). The IgA responses in mice
immunized by the i.n. route with the antigen preparations
persisted for 8 weeks following initial immunization in nasal
and vaginal wash secretions (data not shown).
3.6. Immunoblot Reactivity with Polyclonal Antibodies. As
showninFigure 6(a),weobservedimmunoreactivitypresent
in the IgG antibodies from the sera of mice after i.n. and
i.n./i.m. in a prime-boost immunization using diﬀerent
toxoids against OMP of N. meningitidis. The main antigensThe Scientiﬁc World Journal 7
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Figure 4: Concentration of speciﬁc anti-OMPs IgA in saliva and vaginal washes of adult mice immunized i.n./i.m. at 42 days, 7 days post the
i.m. prime-boost. (a) IgA saliva. (1) IgA saliva antibodies in normal mice; (2) IgA saliva antibodies pooled from nine mice immunized with
OMPs and Stx1; (3) IgA saliva antibodies pooled from eight mice immunized with OMPs and Stx2; (4) IgA saliva antibodies pooled from
ten mice immunized with OMPs and CT (b) IgA of vaginal washes. (1) IgA vaginal washes antibodies in normal mice; (2) IgA vaginal washes
antibodies pooled from nine mice immunized with OMPs and Stx1; (3) IgA vaginal washes antibodies pooled from eight mice immunized
with OMPs and Stx2; (4) IgA vaginal washes antibodies pooled from ten mice immunized with OMPs and CT. Each scale bar represents the
mean ± SE of mice per group in an experiment representative of two separate experiments. (a) OMPs and stx1 IgA containing formulations
saliva versus vaginal washes (P<0.001). (b) OMPs and stx2 IgA containing formulations saliva versus vaginal washes (P<0.001). (c) OMPs
and CT IgA containing formulations salivaversus vaginal washes (P<0.05).
recognized by IgG antibodies were PorA (class 1), PorB (class
2), RmpM (class 4), Opa (class 5), and Neisserial surface
protein A (NspA). As shown in Figure 6(b), we also observed
immunoreactivity of IgG antibodies against the A subunits
of Stx1 and Stx2 toxoids. The molecular position of the A
subunit changed, which could have been attributed to the
treatment used in toxoid preparation. In Figure 6(a)(2), we
saw IgG reactivity with OMP and Stx1 at 28 days after i.n.
immunization and in Figure 6(a)(3) we saw IgG reactivity
with OMP and Stx1 at 42 days, 7 days post the i.m. prime-
boost.InFigure 6(a)(5),wesawIgGreactivitywithOMPand
Stx2 28 days after i.n. immunization and in Figure 6(a)(6)
with OMP and Stx2 42 days, 7 days post the i.m. prime-
boost. In Figure 6(a)(1) we saw normal sera of neonate
mice 12 days and 6(a)(2) normal sera of adult mice. In
Figure 6(b)(1), we saw IgG reactivity with Stx1 at 28 days
after i.n. immunization and in Figure 6(b)(2) IgG reactivity
ith Stx1 at 42 days, 7 days post the i.m. prime-boost. In
Figure 6(b)(3), we saw IgG reactivity with Stx2 28 days after
i.n. immunization and in Figure 6( b ) ( 4 )S t x 24 2d a y s ,7d a y s
post the i.m. prime-boost.
3.7. Determination of the Cytokines in BALB/c Mice. To
examine whether type 1 (IFN-γ) and type 2 (IL-6) cytokine
proﬁles were diﬀerentially secreted in BALB/c mice, spleen
cell supernatants were analysed 20, 48 and 72h after i.m.
immunizationwithOMP-Stx1or-Stx2inordertodetermine
the presence of cytokines by capture ELISA. We used 1 or
2μg of OMP. As shown in Figure 7, BALB/c mice immunized
with OMP of N. meningitidis and Stxs showed mixed type
1 and type 2 cytokine responses. Comparing cytokine levels
present in the control mice, we could verify that, despite8 The Scientiﬁc World Journal
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Figure 5: Level of IgG1, IgG2a, and IgG2b antibodies present, determined by ELISA, in mouse sera of BALB/c immunized with (a) OMPs of
N.meningitidisandstx1(b)OMPsofN.meningitidisandstx2and(c)CT,at42days,7dayspostthei.mprime-boost.NS:normalmousesera
as control. Each scale bar represents the mean ± SE of nine to ten mice per group per group in an experiment representative of two separate.
(a) OMPs and stx1-IgG1, IgG2a, and IgG2b containing formulations versus normal sera (P<0.001). (b) OMPs and stx2 IgG1, IgG2a, and
IgG2b containing formulations versus normal sera (P<0.001). (c) OMPs and CT IgG1, IgG2a, and IgG2b containing formulations versus
normal sera (P<0.05).
the Stx1 or Stx2 toxoids used, high levels of type 1 and
type 2 cytokines were produced independently of the dose
used. Moreover, all i.n.-vaccinated groups showed higher
IFN-γ production when compared to unimmunized mice.
IFN-γ mediates diverse functions in bone marrow-derived
phagocytes, including phagocytosis and microbe destruc-
tion. This cytokine has also been detected at implantation
sites under both physiological and pathological conditions
in many diﬀerent species. Cytokines IFN-γ and IL-6 were
producedbyspleencellsuponinvitrorecallwiththeOMPof
N. meningitidis a n dw e r ed e t e c t e db ys p e c i ﬁ cin vitro assays.
3.8. Bactericidal Activity. The bactericidal activity of each
serum was assessed against the meningococcal homologous
strain B:4:P1.15,19,5.5,L379,1,8. Bactericidal activity was
assayed relatively with the antibodies raised against OMP of
N. meningitidis. Table 1 shows the bactericidal titers of the
antibodies. Sera collected after i.n. immunization showed
lower antibody titers compared to the i.m. immunization.
We observed a signiﬁcant diﬀerence between the bactericidal
antibody response after the i.m. dose compared with the
i.n dose. These data suggest that high levels of bactericidal
antibodies were produced that are speciﬁc for OMP. The
controls showed a lower bactericidal activity than that
observed in the experimental groups.
3.9. IgG and IgM Avidity. To investigate the type of antibody
response produced, we determined the IgG and IgM avidity
index (AI) after i.n. and i.m. immunization in all of the stud-
ied groups. We foundthatthe AIof the IgMand IgG isotypes
did not diﬀer signiﬁcantly between the diﬀerent adjuvants
used. Additionally, we observed a good correlation between
AI and bactericidal activity after i.n. or i.m. immunization.
Interestingly, we also observed a good correlation between
the bactericidal activity of postimmunization sera samples
and the antibodies produced against OMP. Our data suggestThe Scientiﬁc World Journal 9
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Figure 6: Immunoblot reactivity showing IgG antibodies binding to OMPs of N. meningitidis. (a)(1)–(6) With OMPs of N. meningitidis (B:
4:P1.15,19,5.5,L379,1,8) 28 days after i.n. immunization in the presence of stx1 (a)(1) or stx2 (a)(2). Immunization-speciﬁc IgG antibody
responsesat42days,7dayspostthei.mprime-boostinthepresenceofstx1(a)(5)andstx2(a)(6)asadjuvantsinserum.Immunoreactivityof
normal sera used as a control in (1,4). In (b)(1,2), immunoblot with sera of BALB/c mice immunized with OMPs and toxoids. IgG reactivity
with(1)OMPsandstx128daysafteri.n.immunization(2)OMPandstx142days,7dayspostthei.mprime-boostand(b)(3,4)immunoblot
with sera of BALB/c mice immunized with OMPs and toxoids. IgG reactivity with (1) OMPs and stx2 28 days after i.n. immunization (2)
OMPs and stx2 42 days, 7 days post the i.m prime-boost. Molecular weight marker is on the left of (a).
Table 1: SBA in groups of mice after prime i.n. and boost i.m. with meningococcal OMP+Stx1 or OMP+Stx2 or OMP+CT.
Routes Unimmunized mice∗ OMP+Stx1 OMP+Stx2 OMP+CT
Intranasally 4 — 16 — 8 — 4 —
Intramuscularly — 2 — 164 — 512 — 128
∗Normal serum from neonatal unimmunized mice or adult mice.
that use of these adjuvants resulted in the production IgG
and IgM antibodies of high avidity (Table 2) .T h eA Iw a s
considered during the analysis of the results as follows: AI
valueslessthan0.29weredesignatedaslowavidity,0.30–0.49
weredesignatedasintermediateavidity,andgreaterthan0.50
were high avidity.
4. Discussion
This study demonstrated that Stx1 and Stx2 toxoid-based
vaccines combined with OMP of N. meningitidis Br e s u l t e d
in a dramatic improvement in the use of Stx1 and Stx2 as
toxoid delivery systems as adjuvants, with the production of
antibodies of high avidity and bactericidal activity against
N. meningitidis B in neonatal mice using a prime-boost
immunization schedule. This vaccine formulation was also
eﬃcient in inducing the production of IFN-γ and IL-6.
Speciﬁcally, following i.n./i.m. immunization of mice with
vaccine preparations compared with OMP plus the cholera
toxin B subunit, we also observed increased production of
IgG2a/2b versus IgG1 Abs, as well as IFN-γ, indicating the
induction of a Th1 response. Thus, these data indicate a
mixed Th1/Th2 immune response. This observation also
has important ramiﬁcations for vaccine development against
meningococcus. The results demonstrate that Stx1 and
Stx2 induced speciﬁc antibody responses with bactericidal
activity. The neutralization of toxicity occurred without
compromising immunogenicity.
In practice, however, designing and producing aﬀordable
new vaccines against existing pathogens is time consuming,
expensive, and without guarantee of success. The ability
to elicit vaccine antigen-speciﬁc immune responses of the
appropriatetypeandmagnitudeisakeyissueinvaccinology.
This issue is compounded somewhat by the propensity of
neonates and adults to respond diﬀerently to the same
vaccine preparations [34].
We know that there is a great need for immunolog-
ical adjuvants or vectors that are capable of stimulating
both antibody and cytolytic T lymphocyte responses to
vaccine antigens. An interesting work showed that StxB of
S. dysenteriae was a powerful vaccine delivery system for
polyepitopic antigens that can elicit antigen-speciﬁc CTLs,
humoral immune responses, and Th1 polarization without
the use of adjuvants to tumor or viral infection [35, 36].
As described previously, the choice of administration
route may be very important for eﬀective induction of
mucosal immune responses. Mucosal vaccines delivered
into the nasal tract provide several advantages. Intranasal
immunization eﬀectively induces not only systemic IgG but
also secretory IgA responses in mucosal eﬀector tissues.
In this study, i.n. immunization induced higher levels of
secretory IgA and IgM in secretions than systemic IgG, IgM,
and IgA. In addition, i.n. immunization may involve less of
a risk of anaphylactic reactions, since the doses used in i.n.
immunization induce lower total and antigen-speciﬁc IgE
levelsinserum[37,38].Anotherpointthatwillbeimportant10 The Scientiﬁc World Journal
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Figure 7: Production of IFNγ and IL-6 in adult BALB/c mice after four i.n. doses of 20μgo fO M Po fN. meningitidis and 2μgo f( a )
Stx1 toxoid, (b) Stx2 toxoid, or (c) CT. The spleen cultures were stimulated in vitro with 1 or 2μg of the homologous antigen used
for immunization, and the supernatants were harvested after 48h, and 72h of culture for IFN-γ or 20h, 48h and 72h for IL-6. IFN-
γ concentrations are expressed in ng/mL. IL-6 concentrations are expressed in pg/mL. Normal cells∗ and concanavalin A were used as
controls.
to analyze in future studies is the mechanism(s) by which
these toxoids stimulate the mucosal immune responses, as
this has remained largely obscure to date. Thus, intranasal
vaccination using the new toxoids as adjuvants may be useful
in meningococcal human disease prevention, although it
remains to be determined whether the antibody responses
elicited in humans will be suﬃcient to confer protection.
As we know, the design of protein-based meningococcal
vaccines is complicated by the high level of genetic and anti-
genic diversity of meningococcus. Because it is naturallyThe Scientiﬁc World Journal 11
Table 2: Avidity index of IgG and IgM antibodies of immunized mice by intranasally and intramuscularly routes.
Routes Unimmunized mice∗ OMP+Stx1 OMP+Stx2 OMP+CT
IgG IgM IgG IgM IgG IgM IgG IgM
Intranasally 0.16 0.13 0.82 0.65 0.94 0.78 0.42 0.35
Intramuscularly 0.12 0.13 0.45 0.69 0.84 0.65 0.33 0.38
Avidity index values: <0.29: low avidity; 0.30–0.49: intermediate avidity; >0.50: high avidity.
competent for genetic transformation and recombination,
meningococcus has a complex population structure reﬂect-
ing the combined impact of accumulated mutations and
horizontal genetic exchange [39].
In a recent interesting review, Feavers and Pizza [39]p r e -
sentedacomparisonwiththedevelopmentandimplementa-
tion of other vaccines against bacterial diseases of the young
and highlighted the slow progress toward the prevention of
group B meningococcal disease through vaccination.
OnlyOMVvaccineshavebeenused,ostensiblytodisrupt
clonal outbreaks, but because of the restricted range of
protection they oﬀer against diverse hypervirulent lineages,
their use in routine immunization programs has been
limited. Emerging evidence suggests that meningococcal
component vaccine formulations are likely to consist of
multiple antigens [39].
In the case of abundant immunodominant antigens,
which tend to be antigenically variable, vaccines are likely to
consistofanumberofantigenicvariantssothattheyoﬀerthe
required breadth of coverage against diverse meningococcal
isolates [40]. In the case of the less abundant and less
variable antigens, vaccines are likely to consist of multiple
components to take advantage of synergistic eﬀects. New
meningococcal vaccine formulations may also include novel
adjuvants to ensure potent bactericidal antibody responses
[27, 33].
How relevant these observations are to protection needs
more studies. Meanwhile, we observed the production of
antibodies with bactericidal activity and high avidity inde-
pendent of the toxoid used. As we know, the heat-labile
enterotoxins have attracted considerable attention due to
theirexceptionalmucosaladjuvantproperties,althoughtheir
intrinsic enterotoxicity precludes their use as adjuvants for
human vaccines [41].
In this study, the priming eﬀect of OMP and Stx1 or Stx2
used as adjuvants did not seem to be similar in intensity
and quality to antibodies produced for OMP antigens. The
same seemed to be true in the induction of IFN-γ and IL-
6 when Stx1 or Stx2 was used as adjuvants. These results
suggest that Stxs can be safely used as a priming stimulus
in neonatal animals in a prime-boost strategy to control
meningococcalinfection.Here,fortheﬁrsttime,Stx1orStx2
was shown to be eﬀective and safe mucosal adjuvants for the
development of a nasal meningococcal immune response.
The altered toxicity of Stx1 or Stx2 toxin might be closely
related to a potent adjuvant action with antibody responses
to OMP antigens of N. meningitidis B.
These data suggest the possibility of intranasal immu-
nization with meningococcal antigens and toxoids Stx1 and
Stx2 adjuvants as a new strategy in mucosal immunization.
Another important point is that to what extent such
dichotomy between localization of Th1 and Th2 cells occurs
in mucosal inductive and eﬀector tissues that remains to be
determined.
Another important point in our studies was the antigen
speciﬁcity of the mouse IgG response to OMP of N. menin-
gitidisusing Stx1 and Stx2 by immunoblotting. The immune
responses were principally directed to class 1(PorA), class 2
(PorB), and Opa class 5 proteins of N. meningitidis.I tw a s
particularly noteworthy that mice that responded with high
ELISA titers had high antibody avidity levels. The subclass
response was to IgG1, IgG2a, and IgG2b. The class 1 protein
is, therefore, an important antigen for inclusion in an OMP
vaccine for several studies described in the literature.
Our studies using detoxiﬁed subunits of Stx1 or Stx2
agreed with the results of ˚ Agren et al. [42] and indicated that
the neutralization of the cytotoxicity was mainly due to the
A subunit. On the other hand, an association between the
cytotoxicity of the protein and its ability to induce cytokine
release has already been suggested [43].
However, application of the toxoids or their subunits as
adjuvants for human use requires an understanding of their
mode of action and the separation of their desirable immun-
omodulatory properties from their toxicity [44]. It has been
shown that the adjuvant action is not critically dependent
upon the enzymatic activity of the A subunit, and that the
isolated B subunit may exert diﬀerent eﬀects on cells of the
immune system than do the intact toxins [45]. However,
immunomodulatory eﬀects of the enterotoxin and its sub-
units can result in the enhancement of immune responses
and thus can be considered as immunoregulatory agents
[45]. Immunomodulatory mechanisms mediated by each
subunit of the holotoxin give a better understanding of the
toxin’s eﬀect on the immune system and for application of
these subunits as vaccine candidates, either as an adjuvant or
as a vector [35].
Although characterizing the mechanisms involved in
regulating mucosal immune responses has proven diﬃcult,
the availability of deﬁned molecular probes, including
enterotoxin derivatives, has provided new opportunities for
research in this ﬁeld of investigation [35, 46].
The bacterium O157:H7 is known to be the most
important STEC serotype in many industrialized countries,
hundreds of distinct STEC serotypes have been isolated from
human diseases in many geographic areas, including Brazil,
and, of the 20 distinct serotypes identiﬁed, more than 50%
corresponded to serotypes associated with human diseases
[47]. As we know, the outer membrane of meningococcus is12 The Scientiﬁc World Journal
considered a good adjuvant [48]. As our preliminary results
and previous studies have shown, antibodies protect against
STEC infection (data not shown). Additionally, studies are
under way in our laboratory using other animal models,
including adult mice and rabbits.
As we know, the major enterotoxins produced by V.
cholerae and E. coli, CT and LT, respectively, have continued
tobethemoststudiedmucosaladjuvants[36].TheBsubunit
of molecules binds to cell surface gangliosides and this could
enhance immune response by increasing the permeability of
epithelial membranes.
As the major enterotoxins studied in the literature, with
this new toxoids of STEC E.coli we hoped to open the
opportunity to introduce new adjuvants, especially for N.
meningitidis B. As recently pointed out by two experts in the
area of meningococcus, when we compare the development
and implementation of other vaccines against bacterial
diseases of the young, progress towards the prevention of
group B meningococcal disease through vaccination it has
been considered slow. Only OMV vaccines have been used,
ostensibly to disrupt clonal outbreaks, but because of the
restricted range of protection they oﬀer against diverse
hypervirulent lineages, their use in routine immunization
programs has been limited. In addition to the study of new
meningococcal vaccine formulations, they also emphasize
the use of novel adjuvants to ensure potent bactericidal
antibody responses.
Finally, our results demonstrated an interesting result
thatOMPandthetoxoidsStx1orstx2usedasadjuvantswere
recognized by immunoblot at 28 days, after a prime, and at
42 days after the prime-boost schedule used in the present
investigation, the neisserial surface Porin A and (NspA) was
ﬁrst identiﬁed using a monoclonal antibody and is a highly
conserved, and surface-exposed outer membrane protein of
N. meningitidis has been shown to induce a bactericidal
immuneresponseinanimalsagainstallpathogenicNeisserial
serogroups obtained following the immunization of mice
withanoutermembranepreparation[49].Ithasaconserved
primary structure, is expressed by most meningococci, and
elicits antibodies with bactericidal activity against diverse
meningococcal isolates in mice. More studies are necessary
in order to understand the importance of this antigen at
a mucosal level. Additionally, the immunization schedule
in the present investigation produced IgG antibodies that
recognized PorA, PorB, RmM, and OpA, studied for their
importanceinseveralvaccinesuseduntilthistime,especially
for N. meningitidis B[ 49].
As we know, since the publication of the entire genome
of N. meningitidis at the beginning of this decade, several
studies focusing on alternative antigens to compose a new
vaccine against N. meningitidis serogroup B (Men B) have
been described [40]. Meanwhile, we do not have a good
vaccine that gives a good protection in all ages. The degree
of strain- and serosubtype-speciﬁc responses varies with age,
so only OMV vaccines have been used, ostensibly [50].
The discovery of new adjuvants, as in our study, repre-
sents a major step in our understanding of a new protective
vaccine that induces responses at mucosal surfaces. However,
there are still many unanswered questions, such as how the
mechanisms operate at the mucosal level as well as several
adjuvants described in the literature. In addition, we know
that we have diﬀerent types/strains of meningococcus B
bacteria, so a universal vaccine against all types is a goal. A
g r e a td e a lo fw o r kn e e d st ob ed o n eo nt h ep r e c i s er e g u l a t o ry
mechanisms that govern the eﬃcient generation of new
vaccines against this pathogen.
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